Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Vice President, Finance | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 230,118 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 30,000 · Balance 230,118 F1: The 30,000 shares of restricted common stock will fully vest on August 3, 2027, subject to Mr. Carson's continued service on such date. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 30,000 shares of restricted common stock will fully vest on August 3, 2027, subject to Mr. Carson's continued service on such date.
F2: Includes shares of restricted common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 21:26 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-091279 · tm2622360-1_4seq1.xml · nonDerivative · entry 1 Carson Michael J. · CIK 0001896079 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,118 F1 · shares: The 30,000 shares of restricted common stock will fully vest on August 3, 2027, subject to Mr. Carson's continued service on such date. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 21:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 61,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002489 · tm262288-1_4seq1.xml · nonDerivative · entry 1 Carson Michael J. · CIK 0001896079 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,118 F1 · shares: The 61,200 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:10 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 51,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000910 · tm251747-2_4seq1.xml · nonDerivative · entry 1 Carson Michael J. · CIK 0001896079 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,918 F1 · shares: The 51,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates. F2 · balance_after: Includes 138,918 shares of restricted common stock. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 20:59 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | SaleCommon Stock | 2,755 | $8.16 | $22,478.05 |
DisclosureSEC source: 0001104659-24-115837 · tm2427970-1_4seq1.xml · nonDerivative · entry 3 Carson Michael J. · CIK 0001896079 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,918 F4 · kind: In connection with the vesting of 9,100 shares, 2,755 shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Carson's tax withholding obligations. Mr. Carson had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| January 04, 2024 Filed Nov 8, 2024 20:59 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 34,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-115837 · tm2427970-1_4seq1.xml · nonDerivative · entry 2 Carson Michael J. · CIK 0001896079 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,673 F3 · shares: The 34,567 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| January 03, 2023 Filed Nov 8, 2024 20:59 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 28,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-115837 · tm2427970-1_4seq1.xml · nonDerivative · entry 1 Carson Michael J. · CIK 0001896079 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,106 F1 · shares: The 28,806 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.